These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 15173090

  • 1. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients.
    Xia W, Chen JS, Zhou X, Sun PR, Lee DF, Liao Y, Zhou BP, Hung MC.
    Clin Cancer Res; 2004 Jun 01; 10(11):3815-24. PubMed ID: 15173090
    [Abstract] [Full Text] [Related]

  • 2. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis.
    Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL.
    Clin Cancer Res; 2003 Feb 01; 9(2):594-600. PubMed ID: 12576423
    [Abstract] [Full Text] [Related]

  • 3. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
    Yang W, Klos KS, Zhou X, Yao J, Yang Y, Smith TL, Shi D, Yu D.
    Cancer; 2003 Sep 15; 98(6):1123-30. PubMed ID: 12973835
    [Abstract] [Full Text] [Related]

  • 4. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG.
    Anticancer Res; 2004 Sep 15; 24(3b):2061-8. PubMed ID: 15274401
    [Abstract] [Full Text] [Related]

  • 5. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells.
    Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC.
    Nat Cell Biol; 2001 Mar 15; 3(3):245-52. PubMed ID: 11231573
    [Abstract] [Full Text] [Related]

  • 6. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM.
    Clin Cancer Res; 2004 Nov 15; 10(22):7621-8. PubMed ID: 15569994
    [Abstract] [Full Text] [Related]

  • 7. Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer.
    Puhalla H, Wrba F, Kandioler D, Lehnert M, Huynh A, Gruenberger T, Tamandl D, Filipits M.
    Anticancer Res; 2007 Nov 15; 27(3B):1679-84. PubMed ID: 17595796
    [Abstract] [Full Text] [Related]

  • 8. Study of HER2/neu status in Qatari women with breast carcinoma.
    Rasul KI, Mohammaed K, Abdalla AS, Chong-Lopez A, Ahmad MA, Al-Homsi MU, Al-Hassan AM, Al-Alosi AS, Bener A.
    Saudi Med J; 2003 Aug 15; 24(8):832-6. PubMed ID: 12939666
    [Abstract] [Full Text] [Related]

  • 9. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C, von Struensee D, Bierer S, Bögemann M, Hertle L, Eltze E.
    Aktuelle Urol; 2005 Sep 15; 36(5):423-9. PubMed ID: 16163605
    [Abstract] [Full Text] [Related]

  • 10. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS, Kim SW.
    Oncol Rep; 2007 Jul 15; 18(1):139-43. PubMed ID: 17549359
    [Abstract] [Full Text] [Related]

  • 11. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
    Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM.
    Clin Cancer Res; 2004 Aug 01; 10(15):5168-77. PubMed ID: 15297421
    [Abstract] [Full Text] [Related]

  • 12. Expression levels and clinical-pathological correlations of HER2/neu in primary and metastatic human breast cancer.
    Stefano R, Agostara B, Calabrò M, Campisi I, Ravazzolo B, Traina A, Miele M, Castagnetta L.
    Ann N Y Acad Sci; 2004 Dec 01; 1028():463-72. PubMed ID: 15650272
    [Abstract] [Full Text] [Related]

  • 13. Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1).
    Hermanová M, Lukás Z, Nenutil R, Brázdil J, Kroupová I, Kren L, Pazourková M, Růzicka M, Díte P.
    Neoplasma; 2004 Dec 01; 51(2):77-83. PubMed ID: 15190415
    [Abstract] [Full Text] [Related]

  • 14. High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome.
    Schmitz KJ, Grabellus F, Callies R, Otterbach F, Wohlschlaeger J, Levkau B, Kimmig R, Schmid KW, Baba HA.
    Breast Cancer Res; 2005 Dec 01; 7(2):R194-203. PubMed ID: 15743500
    [Abstract] [Full Text] [Related]

  • 15. The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients.
    Al-Moundhri MS, Nirmala V, Al-Hadabi I, Al-Mawaly K, Burney I, Al-Nabhani M, Thomas V, Ganguly SS, Grant C.
    J Surg Oncol; 2005 Sep 15; 91(4):243-52. PubMed ID: 16121348
    [Abstract] [Full Text] [Related]

  • 16. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald MJ, Stratowa C, Kaserer K, Schreiber M.
    Clin Cancer Res; 2005 Dec 01; 11(23):8348-57. PubMed ID: 16322295
    [Abstract] [Full Text] [Related]

  • 17. Expression of HER2 and its association with AP-2 in breast cancer.
    Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V, Kellokoski J, Eskelinen M, Kosma VM.
    Eur J Cancer; 2004 Jul 01; 40(10):1485-95. PubMed ID: 15196531
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
    Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, Löning T.
    Clin Cancer Res; 2006 Jan 01; 12(1):159-68. PubMed ID: 16397038
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.